New Study on Thiazolidinediones May Show Benefits

Elliott, William T.
June 2008
Travel Medicine Advisor;Jun2008, Vol. 18 Issue 6, p1
The article reports on a study that aimed to show the benefits of thiazolidinediones. According to it, pioglitazone slows progression of coronary atherosclerosis compared to glimepiride in patients with type 2 diabetes. Meanwhile, some athletes have turned to growth hormones for performance enhancement since they are difficult to detect.


Related Articles

  • Pioglitazone reduced carotid intima-media thickness in patients with diabetes. Haigh, Christen // Cardiology Today;Jan2008, Vol. 11 Issue 1, p14 

    The article focuses on a study which examined the effectiveness of pioglitazone in reducing carotid intima-media thickness in patients with type 2 diabetes. The study compared the effects of pioglitazone and glimepiride on measures of atherosclerosis. It included 462 patients who were randomly...

  • Aspirin for all? Not so fast... Kuritzky, Louis // Clinical Oncology Alert;Feb2009 Supplement, Vol. 14 Issue 2, p3 

    The article discusses research being done on the effectiveness of acetylsalicylic acid (ASA) versus placebo in Japanese type 2 diabetics. It references a study by H. Ogawa et al published in a 2008 issue of the "Journal of American Medical Association." Particular focus is given to the primary...

  • Exenatide (Byetta) Has Rapid, Powerful Anti-inflammatory Effect, UB Study Shows Anti-inflammatory effect occurs independently of weight loss. Goldbaum, Ellen // Biomedical Market Newsletter;11/9/2011, Vol. 21, p566 

    The article reports on a study which examines the benefit of exenatide drug to patients with type 2 diabetes. Findings reveal that the said drug has a strong and rapid anti-inflammatory effect aside from its function to improve blood sugar level. It notes that the new discovery showed the...

  • Vildagliptin: profile report. Mueller, Tanja; Barkun, Alan N // Drugs & Therapy Perspectives;Mar2007, Vol. 23 Issue 3, p4 

    Adapted and reproduced from Drugs 2006; 66 (15): 1989-2004[1-4]

  • Rimonabant: An Answer to Obesity in Diabetes? Kuritzky, Louis // Internal Medicine Alert;1/15/2007, Vol. 29 Issue 1, p7 

    The article discusses research being done on the effectiveness of rimonabant for obese patients with type 2 diabetes.

  • OPTIMUS-3: Prasugrel bested off-label doses of clopidogrel in small population of patients with type 2 diabetes. Raible, Eric; Rusk, Judy; Southall, Jennifer // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p43 

    The article discusses research on the efficacy of a 60-milligram (mg) loading dose and 10-mg maintenance dose of prasugrel against a 600-mg loading dose and 150-mg maintenance dose of clopidogrel in patients with type 2 diabetes and coronary artery disease, presented by Dominick Angiolillo at...

  • New Study on Thiazolidinediones May Show Benefits. Elliott, William T. // Primary Care Reports;Jun2008, Vol. 14 Issue 6, p1 

    This section offers news briefs concerning pharmacology. A study on the effects of pioglitazone on the development of coronary atherosclerosis in type 2 diabetes patients found that the drug has the potential to improve cardiovascular outcomes. A meta-analysis by a group from Stanford University...

  • Association of serum omentin levels with cardiac autonomic neuropathy in patients with type 2 diabetes mellitus: a hospital-based study. Chan-Hee Jung; Sang-Hee Jung; Bo-Yeon Kim; Chul-Hee Kim; Sung-Koo Kang; Ji-Oh Mok // Cardiovascular Diabetology;10/14/2015, Vol. 14 Issue 1, p1 

    Background: Whereas a few studies have reported associations of serum omentin levels with subclinical atherosclerosis in patients with diabetes, little information is available with respect to the associations of serum omentin levels and diabetic microvascular complications. The aim of this...

  • Diabetes drug choices may have genetic link. Baines, Emma // GP: General Practitioner;10/20/2003, p7 

    The effectiveness of drug treatment for type-2 diabetes depends on the cause of their condition, a Great Britain trial has shown. It found that sulphonylureas are four times as effective as metformin in patients with a genetic variant that causes them to develop type-2 diabetes earlier in life....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics